Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERBIOTAX
2024-514953-31-00Phase 2Authorised
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Cetuximab monotherapy with Cetuximab + weekly paclitaxel (2 arms). Primary endpoint: Objective response rate (ORR). Planned start Feb 2025; status: authorised.
02
Drugs
cetuximabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-514953-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514953-31-00.